NCT02648477View on ClinicalTrials.gov

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 28, 2016

Primary Completion Date

April 1, 2022

Study Completion Date

December 30, 2023

Conditions
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor NegativeProgesterone Receptor PositiveStage IV Breast CancerTriple-Negative Breast Carcinoma
Interventions
DRUG

Anastrozole

Given PO

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Exemestane

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Letrozole

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (6)

91010

City of Hope Medical Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91730

City of Hope Rancho Cucamonga, Rancho Cucamonga

91790

City of Hope West Covina, West Covina

92879

City of Hope Corona, Corona

93534

City of Hope Antelope Valley, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

City of Hope Medical Center

OTHER

NCT02648477 - Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter